AURA ARDON: Open Payments
NPI 1780839787 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,116 in 60 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $180 · 2025 $1,116
Food & beverage: $1,116
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $251 |
| Vanda Pharmaceuticals Inc. | 9 | $168 |
| Supernus Pharmaceuticals, Inc. | 15 | $142 |
| Axsome Therapeutics, Inc. | 4 | $114 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $109 |
| Janssen Pharmaceuticals, Inc | 3 | $103 |
| Lundbeck LLC | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Neurocrine BioSciences, Inc. | 2 | $39 |
| Tris Pharma Inc | 1 | $23 |
Products named: VRAYLAR, FANAPT, Qelbree, Auvelity, CAPLYTA, REXULTI, SPRAVATO, INGREZZA.
Industry payments across CT — which companies pay providers there.
